Ovarian and Gynecologic Cancer Biomarkers

Ovarian and gynecologic cancer biomarkers can help assess cancer risk, classify tumors, guide treatment decisions, monitor disease, and identify inherited cancer susceptibility. This category explores the blood tests, tumor markers, genetic tests, molecular profiles, and pathology biomarkers used across ovarian, cervical, endometrial, vulvar, and other gynecologic cancers. Learn how ovarian cancer markers such as CA-125 and HE4 are interpreted, how ROMA, OVA1, and Overa risk scores are used for adnexal masses, and how BRCA1, BRCA2, BRIP1, RAD51C, RAD51D, and HRD testing can reveal DNA-repair defects and hereditary risk. Coverage also includes ctDNA and minimal residual disease monitoring, along with AFP, beta-hCG, LDH, AMH, and inhibin markers for specific ovarian tumor types. For cervical, endometrial, and vulvar cancers, explore HPV testing, p16 and Ki-67, MMR and MSI, POLE mutations, p53, HER2, and molecular tumor classification. Each guide explains what a test measures, what positive, negative, high, or abnormal results may mean, important limitations, and how biomarker findings fit into diagnosis, prognosis, monitoring, and personalized cancer care.